Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.
Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Jennifer M. King, MD, on findings from a retrospective study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in residual nonretroperitoneal (non-RP) disease post-chemotherapy for nonseminomatous germ cell tumors. Dr King is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at Indiana University (IU) School of Medicine in Indianapolis and a physician-scientist at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis.
Using the Indiana University testicular cancer database, the retrospective analysis revealed that both groups of patients had comparable rates of teratoma or active germ cell tumor in residual non-RP disease. Fifty-five percent of patients with teratoma in the primary tumor site (n=75) had one or more post-chemotherapy non-RP teratomatous elements in their residual disease vs 17% of patients without teratoma in the primary tumor (n = 59). Moreover, 56% of patients without teratoma in the primary tumor had an active germ cell tumor at the time of surgical resection vs 31% of those with primary tumor teratoma.
In our exclusive interview, Dr King discussed the need for improved guidance when determining the appropriate management strategy in residual non-RP testicular cancer, the methodology and patient population included in this retrospective review, and how the presence or absence of teratoma in the primary tumor should not preclude surgical resection in this patient population.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.